Answers are grounded in this paper and cite their sources.
HER2-positive breast cancer is one of the most common types of female breast cancer around the world. This review summarizes information and results of HER2 -positive breast cancer trials and compares their results with the standards in Bosnia and Herzegovina. It is done based on a literature search on PubMed and Google Scholar. This review analyzed trastuzumab as a golden treatment standard for HER2 -positive cancer treatments. Trastuzumab is a monoclonal anti-human epidermal growth factor receptor antibody and besides its effect in the treatment of breast cancer, suggests the treatment with trastuzumab within 1 year. Bosnia and Herzegovina have also accepted standards and guidelines for the treatment of HER2 -positive breast cancer and they are in step with the latest achievements worldwide.
No takes yet. Share an insight, caveat, or question.
Haris Lokvančić (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: